In addition to biomarkers that predict phenoconversion and inform prognosis, biomarkers that can classify participants with tau or TDP-43 pathology may also increase the likelihood of successfully developing effective treatments for FTD. This evidence concerns the gene TARDBP and frontotemporal dementia.